Abstract:Characterization of protein structures at multiple levels plays an essential role in study on protein functions. Structural analysis at the intact protein or intact complex level allows access of information on aspects including level of post-translational modification (PTM), distribution of variants and stoichiometry of binding. Glycosylation is the most common and complex type of PTM, and most natural and therapeutic proteins are glycoproteins. With the increasing level of glycosylation, the heterogeneity of glycoprotein systems increases, the difference in biochemical properties between glycans and polypeptide chains compromises the accuracy of characterization using conventional tools. Mass spectrometry (MS) measures the mass-to-charge ratios of ionized protein species regardless of such difference, while the native MS strategy allows preservation of non-covalent interactions and direct analysis of intact protein and their complexes. However, the accuracy and even feasibility of native MS measurement of intact glycoprotein species are frequently hindered by signal overlapping caused by the wide mass distribution of the heterogeneous proteoforms, and inconsistency of mass profiles between proteoform populations in different charge states due to their differing ionization responses. Although several approaches based on charge reduction were developed to solve these problems, their applicability is limited by the efficiency of charge resolution or availability of electron-based or proton-based gas-phase reaction modules in commercial models of mass spectrometers. In this work, a tandem MS-based approach was used to characterize the intact size variants of an IgA2 monoclonal antibody (mAb) that incorporated non-covalent subunits. This approach utilized both charge reduction effect and the mass balance rule of the dissociation reactions, and employed collision induced dissociation (CID) or higher energy collisional dissociation (HCD) as the fragmentation reaction. Through parallel measurement of this IgA2 system using limited charge reduction approaches for both ensemble and subpopulations of proteoforms, as well as this tandem MS-based approach and cross-validation, the accuracy provided by these approaches was evaluated. The results suggested that when fragments can be released with high specificity and a defined mass, the tandem-MS based approach can provide sufficient accuracy for both charge and mass determination of heterogeneously glycosylated protein complexes at the intact level. This approach may be used as a universal solution to characterization of a larger variety of heterogeneously glycosylated protein systems.

Large-scale identification and quantification of covalent modifications in therapeutic proteins

Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry.

Expanding the structural resolution of glycosylation microheterogeneity in therapeutic proteins by salt-free hydrophilic interaction liquid chromatography tandem mass spectrometry

Efficient discovery of abundant post-translational modifications and spectral pairs using peptide mass and retention time differences

ProteomeTools: Systematic Characterization of 21 Post-translational Protein Modifications by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) Using Synthetic Peptides*

Analysis of Therapeutic Monoclonal Antibody Glycoforms by Mass Spectrometry for Pharmacokinetics Study.

Quantitation and modeling of post-translational modifications in a therapeutic monoclonal antibody from single- and multiple-dose monkey pharmacokinetic studies using mass spectrometry

Optimizing High-Resolution Mass Spectrometry for the Identification of Low-Abundance Post-Translational Modifications of Intact Proteins.

Semi-Automated Glycoproteomic Data Analysis of LC-MS Data Using GlycopeptideGraphMS in Process Development of Monoclonal Antibody Biologics

Identification of Post-Translational Modifications from Serum/Plasma by Immunoaffinity Enrichment and LC-MS/MS Analysis Without Depletion of Abundant Proteins.

“Small is beautiful” – the significance of reliable determination of low- abundant therapeutic antibody glycovariants

Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry

Quantitative Ms Analysis of Therapeutic Mabs and Their Glycosylation for Pharmacokinetics Study

Characterizing Intact IgA2 Antibody and Its Size Variants Using Native Mass Spectrometry and a Tandem MS-based Charge Reduction Approach

Precise Peptide Sequencing and Protein Quantification in the Human Proteome Through in Vivo Lysine-Specific Mass Tagging

N-Terminal Cyclization of Peptides in Large-Scale Protein Identification Based on Biological Mass Spectrometry

"Small is beautiful" – examining reliable determination of low- abundant therapeutic antibody glycovariants

High-Resolution Capillary Zone Electrophoresis with Mass Spectrometry Peptide Mapping of Therapeutic Proteins: Peptide Recovery and Post-translational Modification Analysis in Monoclonal Antibodies and Antibody-Drug Conjugates.

A Turn-Key Approach for Large-Scale Identification of Complex Posttranslational Modifications.

Simultaneous Quantification of Protein Phosphorylation Sites Using Liquid Chromatography-Tandem Mass Spectrometry-Based Targeted Proteomics: a Linear Algebra Approach for Isobaric Phosphopeptides.

Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion